Delving into the molecular choreography underpinning tumour growth, the researchers performed an extensive bulk RNA sequencing analysis of liver tumours extracted from wild-type (WT) and Acly-knockout (Acly-KO) mice across two critical timepoints. Remarkably, even before any measurable reduction in tumour burden was detected, transcriptional changes indicative of immune activation emerged. This early shift implies that ACLY influences the tumour microenvironment more profoundly than previously appreciated, potentially through direct modulation of immune cell infiltration and activation.

The transcriptomic data revealed a consistent downregulation of Acly expression in knockout mice tumours at both early and late stages, with concomitant metabolic reprogramming evidenced by elevated citrate and decreased succinate levels. Such metabolic shifts were accompanied by suppressed expression of pivotal enzymes like succinate-CoA ligase subunits Suclg1 and Sucla2, marking a metabolic phenotype unfavorable for tumour growth. Intriguingly, upregulation of Acss2 was absent, differentiating this hepatic model from other tissue contexts and underscoring tissue-specific metabolic nuances.

A pivotal discovery of this study was the pronounced increase in genes related to leukocyte proliferation, migration, and activation within ACLY-deficient tumours. Gene Ontology clustering of upregulated genes manifested enrichment in immune-related pathways—T cell and B cell activation, interferon alpha and gamma responses, and leukocyte adhesion—signaling an inflamed tumour microenvironment. As tumour volumes remained unchanged at the early timepoint, these immune activations likely precede and contribute causally to tumour suppression.

Expanding upon this, correlation analyses revealed a robust negative association between ACLY expression and tumour-infiltrating B cells across samples. This inverse relationship suggests that ACLY activity may inhibit B cell-mediated antitumour immunity. The implications of this finding are profound, as plasma cells derived from B cells are known to secrete antibodies and orchestrate immune responses, potentially marking ACLY as a metabolic checkpoint that modulates immune surveillance in liver cancer.

To spatially contextualize these transcriptional insights, the team applied cutting-edge spatial transcriptomics to interrogate the tumour microenvironment in both genetic and pharmacologically treated mouse cohorts. This high-resolution technique uncovered a selective surge in B cell populations within tumours lacking ACLY or treated with EVT0185, a novel pharmacological ACLY inhibitor. Notably, other immune populations such as T cells, macrophages, and natural killer T cells did not show similar increases, highlighting a specific enhancement of B cell responses.

Diving deeper into the identity of these B cells, transcriptomic markers revealed a dominance of plasma cells, indicating a skewing towards antibody-producing effector populations. These plasma cells exhibited enriched fatty acid metabolism pathways, an essential feature for their differentiation and function, suggesting that ACLY inhibition may foster a metabolic milieu conducive to plasma cell development and activity within tumours.

An additional highlight in the tumour immune landscape was the elevated expression of Cxcl13, a critical chemokine involved in recruiting B cells to sites of inflammation. The elevation of Cxcl13 in both genetic and pharmacological models implies that ACLY inhibition amplifies chemotactic signals, drawing robust B cell-mediated immune responses into the tumour microenvironment. Given that Cxcl13 levels are typically reduced in human metabolic-associated steatohepatitis-driven HCC, restoring its expression could have meaningful clinical significance.

Supporting these findings, external RNA sequencing datasets from ACLY-deficient DEN-induced tumours cultured in vitro mirrored the increased Cxcl13 expression, reinforcing the reproducibility and biological relevance of these immune alterations. Altogether, the data showcase ACLY as a metabolic gatekeeper that, when inhibited, unleashes a potent B cell-driven antitumour immune response.

From a metabolic standpoint, tumours deficient in ACLY displayed heightened fatty acid and lipid metabolism signatures, consistent with the altered acetyl-CoA flux caused by ACLY disruption. These metabolic rearrangements within hepatocellular carcinoma cells likely support immune activation and plasma cell differentiation, presenting a unique interplay between tumour metabolism and immune modulation.

The therapeutic relevance of these insights is underscored by the efficacy of EVT0185, the ACLY inhibitor, which recapitulated many of the immune and metabolic effects observed in genetic models. Treatment with EVT0185 not only curtailed tumour progression but also enhanced plasma cell infiltration and Cxcl13 expression, spotlighting pharmacological ACLY inhibition as a promising strategy for augmenting tumour immunity in liver cancer.

Together, these findings establish an unanticipated link between the metabolic enzyme ATP citrate lyase and tumour immunogenicity, particularly highlighting its role in suppressing B cell-mediated antitumour immunity. By dismantling this metabolic barrier, ACLY inhibition fosters a tumour microenvironment enriched with antibody-secreting plasma cells and elevated chemokine signaling, culminating in effective tumour suppression.

This study carves a new path in cancer biology by integrating metabolism, immune surveillance, and tumour progression, offering fresh therapeutic avenues for tackling MASH-driven hepatocellular carcinoma. As metabolic regulators like ACLY become recognized as immune modulators, precision oncology stands to benefit from tailored strategies that harness metabolic vulnerabilities to reinvigorate antitumour immunity.

The implications extend beyond liver cancer, raising the possibility that metabolic reprogramming can broadly influence immune landscapes within tumours. Future research will be critical to explore combinatorial therapies that integrate ACLY inhibition with established immunotherapeutic modalities, potentially amplifying clinical efficacy in a range of malignancies.

In summary, inhibiting ACLY disrupts tumour metabolic homeostasis and unlocks B cell-driven immune responses, leading to suppressed tumour growth in liver cancer models. This dual metabolic-immune mechanism heralds a paradigm shift in understanding and treating tumours, positioning ACLY as a vital target for interventions aiming to boost antitumour immunity and improve patient outcomes.

Subject of Research: ACLY inhibition and its effect on tumour immunity and liver cancer progression

Article Title: ACLY inhibition promotes tumour immunity and suppresses liver cancer

Article References:
Gautam, J., Wu, J., Lally, J.S.V. et al. ACLY inhibition promotes tumour immunity and suppresses liver cancer. Nature (2025). https://doi.org/10.1038/s41586-025-09297-0

Image Credits: AI Generated

To dissect the molecular signatures differentiating healthy liver tissues from those affected by non-viral CLD adjacent to HCC lesions, the team employed RNA sequencing (RNA-seq) alongside metabolomic profiling. RNA-seq technology enables researchers to quantify gene expression by sequencing RNA transcripts comprehensively, thereby illuminating which genes are actively transcribed and their relative abundance. By contrasting transcriptomic data between normal and diseased tissue, the researchers identified differential gene expression patterns indicative of altered biological pathways potentially driving HCC pathogenesis.

Simultaneously, metabolomic analysis provided a complementary dimension, cataloging the small-molecule metabolites present within liver specimens. Metabolites reflect the biochemical activity and metabolic flux within cells, revealing perturbations that may not be evident at the gene expression level alone. By integrating transcriptomic and metabolomic data sets—a technique known as multi-omics—the investigators constructed a holistic molecular landscape characterizing the liver’s shift from health to disease, thereby pinpointing critical dysregulated pathways.

The study revealed two distinct molecular subtypes within the CLD category. Subtype 1 was hallmarked by heightened expression of inflammatory markers, signifying a microenvironment rich in pro-inflammatory signaling cascades. This subtype aligns with previous research highlighting chronic inflammation as a predisposing factor for oncogenic transformation within the liver. Conversely, Subtype 2 corresponded to an older patient cohort and was typified by perturbed lipid metabolism, including diminished fatty acid catabolism and increased fatty acid accumulation, coupled with notable metabolite deficiencies. These findings suggest an age-associated metabolic derangement contributing to hepatic carcinogenesis independent of inflammatory processes.

Of particular interest, both CLD subtypes exhibited suppression of genes associated with fatty acid metabolism, highlighting a fundamental metabolic imbalance in disease states. The fatty acid metabolic disruption observed in Subtype 2, alongside the inflammatory milieu of Subtype 1, illustrate diverse, yet convergent, molecular pathways fostering tumor progression. These insights emphasize the heterogeneity inherent in HCC development and challenge the notion of a one-size-fits-all therapeutic intervention.

Leveraging the knowledge of these molecular aberrations, the research team explored therapeutic modalities capable of mitigating the identified pathway dysregulations. One promising candidate is epigallocatechin gallate (EGCG), a potent antioxidant derived from green tea, previously demonstrated in murine models to attenuate expression of inflammatory pathways induced by high-fat diets mimicking non-alcoholic fatty liver disease. EGCG’s potential to reverse inflammatory signaling in Subtype 1 holds considerable promise for chemopreventive applications aimed at reducing HCC incidence within at-risk populations.

Despite these promising findings, the scientists acknowledge the necessity for rigorous clinical validation of therapeutic candidates such as EGCG. Future efforts must prioritize the development of precision medicine approaches tailored to the molecular signature of individual CLD subtypes. For instance, interventions eliminating inflammation may benefit patients classified under Subtype 1, whereas targeted replenishment of metabolite deficiencies could be more effective in the aging-associated Subtype 2 cohort. Such stratified therapy paradigms could revolutionize HCC prevention by addressing the root molecular causes rather than merely managing symptoms or late-stage disease.

This research not only advances our understanding of liver carcinogenesis at the molecular level but also exemplifies the power of multi-omics analysis in biomarker discovery and therapeutic target identification. By integrating transcriptomic and metabolomic data, the team has provided a refined molecular taxonomy of CLD-related HCC risk that will guide future experimental and clinical endeavors. The ability to characterize the disease landscape with such precision marks a significant stride toward curbing the global burden of liver cancer.

Moreover, the study highlights the critical role of meticulous analysis of non-cancerous tissue adjacent to tumors, illuminating the microenvironmental factors that may facilitate malignant transformation. Recognizing that the pathophysiology of liver cancer extends beyond overt tumor cells to encompass surrounding liver tissue invites broader investigative and therapeutic perspectives, opening new windows for early intervention in at-risk individuals.

The collaborative effort behind this study reflects a comprehensive institutional synergy, involving Hiroshima University’s Graduate School of Biomedical and Health Sciences, Hiroshima Prefectural Hospital, and Hiroshima University Hospital. Supported by funding from the Japan Agency for Medical Research and Development as well as the Japan Society for the Promotion of Science, the research epitomizes the intersection of cutting-edge science and clinical relevance.

In summary, the findings from this multi-omics investigation underscore a paradigm shift in understanding non-viral hepatocellular carcinoma development. Distinct inflammatory and metabolic dysregulations characterize different CLD subtypes, each potentially amenable to targeted chemopreventive strategies such as EGCG supplementation. This nuanced insight holds the key to developing bespoke therapies that could substantially reduce liver cancer incidences, ultimately improving patient outcomes globally. As the burden of chronic liver diseases grows with aging populations and lifestyle factors, such scientific advances will be pivotal in transforming the landscape of liver cancer prevention and care.

Subject of Research: Molecular mechanisms of liver dysregulation leading to nonviral-related hepatocellular carcinoma development

Article Title: Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development

News Publication Date: 21-Feb-2025

Web References:
https://pubs.acs.org/doi/10.1021/acs.jproteome.4c00729
https://regeo.org:8443/details.jsp?gseId=GSE77964

References:
Nakahara, H., Ono, A., et al., “Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development,” Journal of Proteome Research, 2025.

Image Credits: Atsushi Ono, Hiroshima University Hospital

Keywords: Hepatocellular carcinoma, Internal medicine, Gastroenterology, Liver, Metabolic disorders